Atossa Genetics To Host Conference Call to Announce Preliminary Results from Phase 1 Study of Topical Endoxifen Thursday, Se...
September 11 2017 - 8:15AM
Atossa Genetics Inc. (NASDAQ:ATOS), a clinical-stage pharmaceutical
company developing novel therapeutics and delivery methods for
breast cancer and other breast conditions, announced today it will
host a conference call on September 14, 2017 at 2 pm EDT to discuss
preliminary results from its Phase 1 dose escalation study of its
proprietary topical Endoxifen. Endoxifen is an active metabolite of
the FDA-approved drug tamoxifen, which is currently used to treat
breast cancer and for breast cancer prevention in high risk
patients.
The objectives of this double-blinded, placebo-controlled,
repeat dose study of 48 healthy female subjects is to assess the
pharmacokinetics of proprietary formulations of both oral and
topical Endoxifen dosage forms over 28 days, as well as to assess
safety and tolerability. The study is being conducted in two parts
based on route of administration.
To listen to the call by phone, interested parties within the
U.S. should call 1-844-824-3830 and International callers should
call 1-412-317-5140. All callers should ask for the Atossa Genetics
conference call. The conference call will also be available through
a live webcast at www.atossagenetics.com. Details for the webcast
may be found on the Company’s IR events page at
http://ir.atossagenetics.com/ir-calendar.
A replay of the call will be available approximately one hour
after the end of the call through October 14, 2017. The replay can
be accessed via Atossa's website or by dialing 877-344-7529
(domestic) or 412-317-0088 (international) or Canada Toll Free at
855-669-9658. The replay conference ID number is 10112105.
About Atossa Genetics
Atossa Genetics Inc. is a clinical-stage pharmaceutical company
developing novel therapeutics and delivery methods to treat breast
cancer and other breast conditions. For more information, please
visit www.atossagenetics.com.
Forward-Looking Statements
Forward-looking statements in this press release, which Atossa
undertakes no obligation to update, are subject to risks and
uncertainties that may cause actual results to differ materially
from the anticipated or estimated future results, including the
risks and uncertainties associated with any variation between
preliminary and final clinical results, actions and inactions by
the FDA, the outcome or timing of regulatory approvals needed by
Atossa, lower than anticipated rate of patient enrollment,
preliminary and final results of clinical studies, the safety and
efficacy of Atossa's products and services, performance of clinical
research organizations and investigators, obstacles resulting from
proprietary rights held by others with respect to fulvestrant, such
as patent rights, and other risks detailed from time to time in
Atossa's filings with the Securities and Exchange Commission,
including without limitation its periodic reports on Form 10-K and
10-Q, each as amended and supplemented from time to time.
Atossa Genetics Company Contact:
Atossa Genetics Inc.
Kyle Guse
CFO and General Counsel
(O) 800-351-3902
kyle.guse@atossagenetics.com
Investor Relations Contact:
Scott Gordon
CoreIR
377 Oak Street
Concourse 2
Garden City, NY 11530
Office: 516.222.2560
scottg@CoreIR.com
Atossa Therapeutics (NASDAQ:ATOS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Atossa Therapeutics (NASDAQ:ATOS)
Historical Stock Chart
From Apr 2023 to Apr 2024